UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AGILA SPECIALTIES INC. AND
MYLAN PHARMACEUTICALS INC.,
Petitioners,

v.

CUBIST PHARMACEUTICALS, INC.,
Patent Owner

Patent No. 8,058,238

Case IPR2015-00143

PETITIONERS' UPDATED EXHIBIT LIST UNDER 37 C.F.R. §42.63

EXHIBIT LIST

Exhibit No.	Reference
1001	High Purity Lipopeptides, U.S. Patent No. 8,058,238 (filed Apr. 24, 2007) (issued Nov. 15, 2011).
1002	High Purity Lipopeptides, U.S. Patent No. 8,129,342 (filed Sept. 22, 2010) (issued Mar. 6, 2012).
1003	File History U.S. Patent No. 8,058,238
1004	File History U.S. Patent No. 8,129,342
1005	Declaration of Catherine N. Mulligan re U.S. Patent No. 8,052,238
1006	Declaration of Catherine N. Mulligan re U.S. Patent No. 8,129,342
1007	Chromatographic Purification Process, U.S. Patent No. 4,874,843 (filed Dec. 3, 1987) (issued Oct. 17, 1989).
1008	Richard H. Baltz, *Lipopeptide Antibiotics Produced by Streptomyces roseosporus and Streptomyces fradiae*, in BIOTECHNOLOGY OF ANTIBIOTICS (W.R. Strohl ed.,1997). ("Baltz")
1009	Peptide Antibiotics, U.S. Patent No. 4,331,594 (filed Nov. 14, 1980) (issued May 25, 1982).
1010	Anhydro- and Isomer-A-21978C Cyclic Peptides, U.S. Patent No. 5,912,226 (filed Dec. 16, 1991) (issued Jun. 15, 1999).
1011	F.M. Huber et al., *The formation of daptomycin by supplying decanoic acid to Streptomyces roseosporus cultures producing the antibiotic complex A21978C*, J. BIOTECHNOL. 7:283-92 (1988).
1012	F.M. Huber et al., *Dispersal of insoluble fatty acid precursors in stirred reactors as a mechanism to control antibiotic factor distribution*, in BIOTECHNOLOGY PROCESSES (Ho and Oldshue eds., 1987).

Exhibit No.	Reference
1013	Catherine N. Mulligan & Bernard F. Gibbs, *Recovery of Biosurfactants by Ultrafiltration*, J. CHEM. TECHNOL. BIOTECHNOL. 47:23-9 (1990).
1014	Sung-Chyr Lin and Horng-Jyh Jiang, *Recovery and Purification of the Lipopeptide Biosurfactant Bacillus subtilis by Ultrafiltration*, BIOTECHNOLOGY TECHNIQUES, 11:413-16 (1997). ("Lin I")
1015	Sung-Chyr Lin et al., *General Approach for the Development of High-Performance Liquid Chromatography Methods for Biosurfactant Analysis and Purification*, JOURNAL OF CHROMATOGRAPHY, 825:145-49 (1998). ("Lin II")
1016	Method of Producing Surfactin with the Use of Mutant of *Bacillus Subtilis*, U.S. Patent No. 5,227,294 (filed June 20, 1991) (issued Jul. 13, 1993).
1017	Mohamad Osman et al., *Tuning micelles of a bioactive heptapeptide biosurfactant via extrinsically induced conformational transition of surfactin assembly*, J. PEPTIDE SCI., 4:449-58 (1998). ("Osman")
1018	F.P. Tally et al., *Daptomycin: A Novel Agent for Gram-positive Infections*, EXPERT OPIN. INVEST. DRUGS 8:1223-38 (1999).
1019	BIOSURFACTANTS: RESEARCH TRENDS & APPLICATIONS (Catherine N. Mulligan ed., 2014).
1020	Sung-Chyr Lin, *Biosurfactant: Recent Advances*, J. CHEM. TECH. BIOTECHNOL. 66:109-20 (1996).
1021	Kei Arima et al., *Surfactin, a crystalline peptide lipid surfactant produced by Bacillus subtilis: Isolation, characterization and its inhibition of fibrin clot formation*, BIOCHEM. BIOPHYS. RES. COMM. 31:488-94 (1968).
1022	Atsushi Kakinuma et al., *Confirmation of the structure of surfactin by mass spectrometry*, AG. BIOL. CHEM. 33:1669-72 (1969).

Exhibit No.	Reference
1023	A.W. Bernheimer et al., *Nature and properties of a cytolytic agent produced by Bacillus subtilis*, J. GEN. MICROBIOL. 61:361-69 (1970).
1024	David G. Cooper, *Biosurfactants*, MICROBIOL. SCI. 3:145-47 (1986).
1025	Dirk Vollenbroich et al., *Antimycoplasma properties and application on cell surface of surfactin, a lipopeptide antibiotic from Bacillus subtilis*, APPL. ENVIRON. MICROBIOL. 63:44-69 (1997).
1026	Catherine N. Mulligan et al., *Selection of microbes producing biosurfactants in media without hydrocarbons*, J. FERMENT. TECHNOL. 62:311-14 (1984).
1027	Catherine N. Mulligan & Bernard F. Gibbs, *Correlation of nitrogen metabolism with biosurfactant production*, APPL. ENVIRON. MICROBIOL. 55:3016-69 (1989).
1028	Catherine N. Mulligan et al., *Enhanced biosurfactant production by a mutant Bacillus subtilis strain*, APPL. MICROBIOL.31:486-69 (1989).
1029	Enhanced Production of Biosurfactant Through the Use of a Mutated B Subtilis Strain, U.S. Patent No. 5,037,758 (filed Jan. 1989) (issued Aug. 6, 1991).
1030	H.E. Reiling et al., *Pilot plant production of rhamnolipid biosurfactant by Pseudomonas aeruginosa*, APPL. ENVIRON. MICROBIOL., 51:985-89 (1986).
1031	Sung-Chyr Lin et al., *Structural and immunological characterization of a biosurfactant produced by Bacillus licheniformis JF-2*, APPL. ENV. MICROBIOL. 60:31-8 (1994).
1032	Jitendra D. Desai and Ibrahim M. Banat, *Microbial production of surfactants and their commercial potential*, MOL. BIOL. REV. 61:47-64, 57 (1997).

Exhibit No.	Reference
1033	Plaintiff's Complaint, Filed October 9, 2013, ECF No. 1. Cubist Pharmaceuticals, Inc. v. Strides, Inc. and Agila Specialties Private Ltd., Case No. 13-cv-1679-GMS (D. Del. filed Oct. 9, 2013).
1034	Proof of Service of Strides, Inc., Filed October 23, 2013, ECF No. 6. Cubist Pharmaceuticals, Inc. v. Strides, Inc. and Agila Specialties Private Ltd., Case No. 13-cv-1679-GMS (D. Del. filed Oct. 9, 2013).
1035	Proof of Service of Agila Specialties Private Limited, Filed October 23, 2013, ECF No. 7. Cubist Pharmaceuticals, Inc. v. Strides, Inc. and Agila Specialties Private Ltd., Case No. 13-cv-1679-GMS (D. Del. filed Oct. 9, 2013).
1036	Plaintiff's Complaint, Filed October 9, 2013 ECF No. 1. Cubist Pharmaceuticals, Inc. v. Strides, Inc. and Agila Specialties Private Ltd., Case No. 13-cv-06016-NLH, (D. N.J. filed Oct. 9, 2013, voluntarily dismissed Oct. 24, 2013).
1037	Plaintiff's Notice of Voluntary Dismissal, Filed October 24, 2013, ECF No.8. Cubist Pharmaceuticals, Inc. v. Strides, Inc. and Agila Specialties Private Ltd., Case No. 13-cv-06016-NLH, (D. N.J. filed Oct. 9, 2013, voluntarily dismissed Oct. 24, 2013).
1038	Memorandum Opinion, Filed December 8, 2014 ECF No. 135. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., Case No. 12-367-GMS, (D. Delaware)
1039	Court Order, Filed December 8, 2014 ECF No. 136. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., Case No. 12-367-GMS, (D. Delaware)

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.